FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2382103665> ?p ?o ?g. }

• W2382103665 abstract "PURPOSE This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. MATERIALS AND METHODS Asymptomatic or mildly symptomatic chemotherapy-naive men with metastatic castration-resistant prostate cancer that progressed on androgen deprivation therapy received 160 mg/d oral enzalutamide or placebo (1:1) until death or discontinuation due to radiographic progression or skeletal-related event and initiation of subsequent therapy. Coprimary end points were centrally assessed radiographic progression-free survival (rPFS) and overall survival (OS). Secondary end points included investigator-assessed rPFS, time to initiation of chemotherapy, time to prostate-specific antigen (PSA) progression, PSA response (≥50% decline), and time to skeletal-related event. RESULTS Of 1,717 total patients, 78 patients were enrolled in Korea (enzalutamide, n=40; placebo, n=38). Hazard ratios (95% confidence interval) for enzalutamide versus placebo were 0.23 (0.02-2.24) for centrally assessed rPFS, 0.77 (0.28-2.15) for OS, 0.21 (0.08-0.51) for time to chemotherapy, and 0.31 (0.17-0.56) for time to PSA progression. A PSA response was observed in 70.0% of enzalutamide-treated and 10.5% of placebo-treated Korean patients. Adverse events of grade ≥3 occurred in 33% of enzalutamide-treated and 11% of placebo-treated Korean patients, with median treatment durations of 13.0 and 5.1 months, respectively. At 13 weeks, the plasma concentration of enzalutamide plus N-desmethyl enzalutamide was similar in Korean and non-Korean patients (geometric mean ratio, 1.04; 90% confidence interval, 0.97-1.10). CONCLUSIONS In Korean patients, treatment effects and safety of enzalutamide were consistent with those observed in the overall PREVAIL study population (ClinicalTrials.gov Identifier: NCT01212991)." @default.
• W2382103665 created "2016-06-24" @default.
• W2382103665 creator A5019918659 @default.
• W2382103665 creator A5020377204 @default.
• W2382103665 creator A5030579517 @default.
• W2382103665 creator A5032267193 @default.
• W2382103665 creator A5035133412 @default.
• W2382103665 creator A5050875866 @default.
• W2382103665 creator A5055008722 @default.
• W2382103665 creator A5090913495 @default.
• W2382103665 date "2016-01-01" @default.
• W2382103665 modified "2023-09-26" @default.
• W2382103665 title "The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients" @default.
• W2382103665 cites W1492157159 @default.
• W2382103665 cites W189198258 @default.
• W2382103665 cites W1904433804 @default.
• W2382103665 cites W1981989535 @default.
• W2382103665 cites W1983944422 @default.
• W2382103665 cites W2003955264 @default.
• W2382103665 cites W2005658600 @default.
• W2382103665 cites W2007824082 @default.
• W2382103665 cites W2051410494 @default.
• W2382103665 cites W2081365151 @default.
• W2382103665 cites W2109783350 @default.
• W2382103665 cites W2112501269 @default.
• W2382103665 cites W2119504728 @default.
• W2382103665 cites W2120292596 @default.
• W2382103665 cites W2139248078 @default.
• W2382103665 cites W2140525590 @default.
• W2382103665 cites W2141569270 @default.
• W2382103665 cites W2148643283 @default.
• W2382103665 cites W2163275129 @default.
• W2382103665 cites W2165542862 @default.
• W2382103665 cites W2165823301 @default.
• W2382103665 cites W2166918329 @default.
• W2382103665 cites W2167331614 @default.
• W2382103665 cites W2320909684 @default.
• W2382103665 cites W2917869996 @default.
• W2382103665 cites W85315641 @default.
• W2382103665 cites W2785982436 @default.
• W2382103665 doi "https://doi.org/10.4111/icu.2016.57.3.174" @default.
• W2382103665 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4869571" @default.
• W2382103665 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27195316" @default.
• W2382103665 hasPublicationYear "2016" @default.
• W2382103665 type Work @default.
• W2382103665 sameAs 2382103665 @default.
• W2382103665 citedByCount "14" @default.
• W2382103665 countsByYear W23821036652017 @default.
• W2382103665 countsByYear W23821036652018 @default.
• W2382103665 countsByYear W23821036652019 @default.
• W2382103665 countsByYear W23821036652020 @default.
• W2382103665 countsByYear W23821036652021 @default.
• W2382103665 countsByYear W23821036652022 @default.
• W2382103665 crossrefType "journal-article" @default.
• W2382103665 hasAuthorship W2382103665A5019918659 @default.
• W2382103665 hasAuthorship W2382103665A5020377204 @default.
• W2382103665 hasAuthorship W2382103665A5030579517 @default.
• W2382103665 hasAuthorship W2382103665A5032267193 @default.
• W2382103665 hasAuthorship W2382103665A5035133412 @default.
• W2382103665 hasAuthorship W2382103665A5050875866 @default.
• W2382103665 hasAuthorship W2382103665A5055008722 @default.
• W2382103665 hasAuthorship W2382103665A5090913495 @default.
• W2382103665 hasBestOaLocation W23821036651 @default.
• W2382103665 hasConcept C121608353 @default.
• W2382103665 hasConcept C126322002 @default.
• W2382103665 hasConcept C126894567 @default.
• W2382103665 hasConcept C143998085 @default.
• W2382103665 hasConcept C2776551883 @default.
• W2382103665 hasConcept C2776694085 @default.
• W2382103665 hasConcept C2780192828 @default.
• W2382103665 hasConcept C2992886853 @default.
• W2382103665 hasConcept C61367390 @default.
• W2382103665 hasConcept C67761136 @default.
• W2382103665 hasConcept C71924100 @default.
• W2382103665 hasConceptScore W2382103665C121608353 @default.
• W2382103665 hasConceptScore W2382103665C126322002 @default.
• W2382103665 hasConceptScore W2382103665C126894567 @default.
• W2382103665 hasConceptScore W2382103665C143998085 @default.
• W2382103665 hasConceptScore W2382103665C2776551883 @default.
• W2382103665 hasConceptScore W2382103665C2776694085 @default.
• W2382103665 hasConceptScore W2382103665C2780192828 @default.
• W2382103665 hasConceptScore W2382103665C2992886853 @default.
• W2382103665 hasConceptScore W2382103665C61367390 @default.
• W2382103665 hasConceptScore W2382103665C67761136 @default.
• W2382103665 hasConceptScore W2382103665C71924100 @default.
• W2382103665 hasLocation W23821036651 @default.
• W2382103665 hasLocation W23821036652 @default.
• W2382103665 hasLocation W23821036653 @default.
• W2382103665 hasLocation W23821036654 @default.
• W2382103665 hasOpenAccess W2382103665 @default.
• W2382103665 hasPrimaryLocation W23821036651 @default.
• W2382103665 hasRelatedWork W2309274182 @default.
• W2382103665 hasRelatedWork W2414042649 @default.
• W2382103665 hasRelatedWork W2831103683 @default.
• W2382103665 hasRelatedWork W2942985299 @default.
• W2382103665 hasRelatedWork W2971490708 @default.
• W2382103665 hasRelatedWork W2996229517 @default.
• W2382103665 hasRelatedWork W3132581442 @default.
• W2382103665 hasRelatedWork W3197069188 @default.
• W2382103665 hasRelatedWork W4229076799 @default.

• next